FIGURE 1.

Study flowchart. The flowchart shows number of subjects with metastatic triple-negative breast cancer (mTNBC) who submitted samples for the PCD4989g clinical study. Of the 670 samples evaluated by PD-L1 IHC, 140 had RNA extracted and CD274 was evaluated by fluidigm. Primary/metastases and anatomic locations were annotated as inscribed by the participating local clinical site. Synchronous: samples collected on the same date; asynchronous: samples collected on different dates. IHC indicates immunohistochemistry; PD-L1, programmed death ligand 1.